Sellas Life Sciences says galinpepimut-S met the Phase 3 REGAL trial’s primary endpoint, reducing death risk by 41% in AML patients in second remission
Observed price moves
- SLS+2.03%10 min after this headline
MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.